NCT04775706 - Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

May 31, 2028

Conditions

Short Bowel Syndrome

Interventions

DRUG

HM15912 Active

Randomized, double-blind, placebo-controlled

DRUG

Placebo

Randomized, double-blind, placebo-controlled

Trial Locations (13)

2100

RECRUITING

Rigshospitalet Department of Digestive Diseases, Transplantation and General Surgery Section for Intestinal Failure, Copenhagen

3000

RECRUITING

UZ Leuven, Leuven

20099

RECRUITING

Asklepios Klinik St. Georg, Hamburg

33000

RECRUITING

Centre Hospitalier Universitaire de Bordeaux, Bordeaux

44195

RECRUITING

The Cleveland Clinic Foundation, Cleveland

60612

RECRUITING

University of Illinois Hospital & Health Sciences System (UI Health), Chicago

69002

RECRUITING

Les Hospices Civils de Lyon, Lyon

72076

RECRUITING

Universitätsklinikum Tübingen, Tübingen

92110

RECRUITING

Hopital Beaujon, Clichy

02115

RECRUITING

Brigham & Women's Hospital, Boston

06300

RECRUITING

Centre Hospitalier Universitaire de Nice, Nice

90-531

RECRUITING

Wojewodzki Specjalistyczny Szpital im. Mikołaja Pirogowa w Łodzi, Lodz

06351

RECRUITING

Samsung Medical Center, Seoul